In a first-of-its-kind pilot in the US, Nolla Health will use AI to diagnose and prescribe acne medications to Utah patients without direct human oversight

A prescription from an AI can now be issued for a medical condition without a doctor's immediate sign-off.

Utah regulators have approved a pilot program allowing Nolla Health to use an AI system to diagnose and prescribe acne medications without direct human oversight. The AI will analyze patient-submitted skin photos and intake information to determine if low-risk acne drugs are appropriate. Initially, a clinician will review the AI's decisions before prescriptions are issued, but the program intends to progress towards fully autonomous AI prescribing. This initiative is part of Utah's broader "AI sandbox" program, which permits regulatory waivers for companies testing AI products under state supervision. Nolla Health, which previously raised $4.5 million in funding, aims to expand its AI-driven treatment capabilities to various medical conditions.

This pilot marks a significant step towards autonomous AI in healthcare, specifically for prescription medication. By allowing AI to diagnose and prescribe for mild-to-moderate acne, Utah is enabling a new model of care that could reduce healthcare costs and improve accessibility for common conditions. The success of this program could pave the way for similar AI-driven diagnostics and treatments across a wider range of ailments, fundamentally changing how routine medical care is delivered.

The regulatory environment in Utah, particularly its AI sandbox program, is setting a precedent for AI innovation in healthcare. Companies like Nolla Health are being empowered to test and deploy advanced AI solutions with state oversight, accelerating the integration of AI into clinical practice. As this technology matures and potentially gains wider approval, it will challenge traditional healthcare delivery systems and prompt a re-evaluation of physician roles and responsibilities in patient care.